# Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

> **NCT06037577** · PHASE1 · COMPLETED · sponsor: **ChemomAb Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)
- Primary Sclerosing Cholangitis (PSC)
- Systemic Sclerosis (SSc)

## Interventions

- **DRUG:** CM-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06037577
- **Lead sponsor:** ChemomAb Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-05
- **Primary completion:** 2019-05-05
- **Final completion:** 2019-05-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06037577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06037577, "Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06037577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*